Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin-Reference-Cited by-同舟云学术

Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

Published:2003-02 Issue:2 Volume:46 Page:222-230
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Gault V. A.,O'Harte F. P. M.,Harriott P.,Mooney M. H.,Green B. D.,Flatt P. R.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-002-1028-x.pdf

Reference46 articles.

1. Ahrén B, Karlsson S (1994) Role of islet neuropeptides in the regulation of insulin secretion. In: PR Flatt, S Lenzen (eds) Frontiers of Insulin Secretion and Pancreatic B-cell Research. Smith-Gordon, London, pp 313–318

2. Flatt PR (1996) Pancreatic B-cells as mediators of metabolic effects of regulatory peptides. Biochem Soc Trans 24:570–575

3. Morgan LM (1996) The metabolic role of GIP: physiology and pathology. Biochem Soc Trans 24:585–591

4. Dupré J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 81:826–828

5. Brown JC (1994) Enteroinsular axis. In: JH Walsh, GJ Dockray (eds) Gut peptides: biochemistry and physiology. Raven Press, New York, pp 765–784

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic exposure to incretin metabolites GLP-1(9−36) and GIP(3−42) affect islet morphology and beta cell health in high fat fed mice;Peptides;2024-08

2. GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology;Peptides;2024-07

3. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?;Journal of Endocrinology;2024-06-11

4. An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits;iScience;2024-04

5. Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes;Peptides;2024-04